Table 2.
Current recruiting clinical trials for cancer vaccines in GI malignancies.
| GI Malignancy | Trial Name | Intervention/Study Arms |
|---|---|---|
| Gastric Cancer | Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment [70] | DC vaccine DC vaccine + CTL DC vaccine + Sintilimab Injection (PD-1 monoclonal ab) |
| Nivolumab, Ipilimumab, and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer—a Combination Immunotherapy Phase Ib Study [71] | OTSGC-A24 + nivolumab OTSGC-A24 + nivolumab + ipilimumab |
|
| A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer [72] | IMU-131 + Cisplatin + 5-FU or Capecitabine IMU-131 + Cisplatin + 5-FU or Capecitabine or Oxaliplatin and Capecitabine Cisplatin + 5-FU or Capecitabine or Oxaliplatin and Capecitabine |
|
| Colorectal Cancer | DC Vaccine in Colorectal Cancer [73] | DC vaccine |
| Intratumoral Influenza Vaccine for Early Colorectal Cancer [74] | Influenza Vaccine | |
| Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer [75] | Autologous dendritic cells loaded with autologous tumour homogenate + Interleukin-2 (IL2) | |
| GVAX for Colorectal Cancer [76] | GVAX | |
| A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC [77] | mFOLFOX6 + nivolumab nivolumab + MVA-BN-CV301 + FPV-CV301 |
|
| Phase 1b Study to Evaluate ATP128, With or Without BI 754091, in Patients With Stage IV Colorectal Cancer [78] | ATP128 + BI 754091 | |
| Trial of PalloV-CC in Colon Cancer [79] | PalloV-CC | |
| HCC | DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma [80] | DNAJB1-PRKACA peptide vaccine + Nivolumab + Ipilimumab |
| “Cocktail” Therapy for Hepatitis B Related Hepatocellular Carcinoma [81] | MSDCV with radical surgery therapy Radical surgery therapy MSDCV with TACE therapy TACE Therapy MSDCV with Sorafenib or Lenvatinib Sorafenib or Lenvatinib |
|
| GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012, and Pembrolizumab in Subjects With Advanced HCC [82] | GNOS-PV02 + INO-9012 + Pembrolizumab | |
| Pancreatic Cancer | Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy ([83]) | Neoantigen Peptide Vaccine + poly IC:LC |
| Clinical Trial on Personalized Neoantigen Vaccine For Pancreatic Cancer ([84]) | Personalized neoantigen vaccine | |
| A Trial of Boost Vaccionations of Pancreatic Tumor Cell Vaccine ([85]) | Neo vaccine Neo vaccine + single dose cyclophosphamide Neo vaccine + metronomic cyclophosphamide |
|
| Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer ([86]) | Cyclophosphamide + GVAX Cyclophosphamide + GVAX + nivolumab Cyclophosphamide + GVAX + nivoulumab + Urelumab |
|
| GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer ([87]) | Cyclophosphamide + nivolumab + GVAX + SBRT | |
| Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery ([88]) | Atezolizumab + RO7198457 + mFOLFIRINOX | |
| Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer ([89]) | Cyclophosphamide + Nivolumab + Ipilimumab + GVAX + CRS-207 Nivolumab + Ipilimumab + CRS-207 |
|
| DC Vaccine in Pancreatic Cancer ([90]) | DC vaccine | |
| Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer ([91]) | Epacadostat + Pembrolizumab + CRS-207 + Cyclophosphamide + GVAX Epacadostat + Pembrolizumab + CRS-207 |
|
| Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer ([92]) | PEP-DC vaccine + nivolumab + gemcitabine/capecitabine | |
| Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.([93]) | SBRT + Nivolumab + CCR2/CCR5 dual antagonist + GVAX SBRT + Nivolumab + CCR2/CCR5 dual antagonist |
|
| Maintenance Therapy With OSE2101 Vaccine Alone or in Combination With Nivolumab, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPAM) ([94]) | FOLFIRI OSE2101 vaccine OSE2101 vaccine + Nivolumab |
DC, dendritic cell; CTL, cytotoxic lymphocyte; 5-FU, fluorouracil; mFOLFOX, modified leucovorin, fluorouracil, oxaliplatin; MVA-BN, modified vaccinia Ankara-Bavarian Nordic; BI, Boehringer Ingelheim; PalloV-CC, Particle-delivered, Allogeneic Tumor Cell Lysate Vaccine for Colon Cancer; MSDCV, Multiple Signals loaded Dendritic Cells Vaccine; TACE, Trans-arterial Chemoembolization; INO, Inovio; Poly LC:IC, carboxymethylcellulose, polyinosinc–polycytidlyic acid, and poly-L-lysin double-stranded RNA; SBRT, Stereotactic Body Radiation; mFOLFIRINOX, modified leucovorin, fluoruracil, irinotecan, oxaliplatin; PEP, personalized peptides; FOLFIRI, folinic acid, irinotecan, 5-FU.